Targets › GCN2
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to low amino acid availability. Plays a role as an activator of the integrated stress response (ISR) required for adaptation to amino acid starvation (By similarity). (UniProt, Q9P2K8)
Open in Phaseline: the race on GCN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HiberCell | HC-7366 GCN2 kinase activator | GCN2 | Phase 1 | Renal Cell Carcinoma | Nov 2026 |
| Deciphera Pharmaceuticals | DCC-2812 GCN2 activator | GCN2 | Phase 1 | Renal Cell Carcinoma | Feb 2029 |
Renal Cell Carcinoma (2)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.